VEGF TKIs used in hepatocellular carcinoma (HCC) treatment, lenvatinib, sorafenib, regorafenib, and cabozantinib are metabolized by CYP3A4, but not all strong inducers/inhibitors have a clinical impact upon them. This evidence concerns the gene VEGFA and hepatocellular carcinoma.